TY - JOUR
T1 - Mechanistic insights into dissolution of highly drug-loaded amorphous solid dispersions of a fast-crystallising drug
AU - Kolisnyk, Tetiana
AU - Mohylyuk, Valentyn
N1 - Publisher Copyright:
© 2026 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license. http://creativecommons.org/licenses/by/4.0/
PY - 2026/7
Y1 - 2026/7
N2 - The dissolution behaviour of fast-crystallizing amorphous solid dispersions (ASDs) at drug loadings (DLs) far exceeding the amorphous solubility limit remains poorly understood. In this study, we investigate how extreme DLs influence dissolution mechanisms in naproxen–copovidone VA64 ASDs prepared by hot-melt extrusion at 20, 50, and 70 wt% DL. Rapid post-extrusion cooling was applied at 70% DL to kinetically suppress crystal growth, while lower DL formulations remained amorphous as confirmed by DSC and PXRD. Drug–polymer interactions were analysed using ATR-FTIR combined with principal component analysis.
Saturation solubility measurements revealed moderate advantages of ASDs over physical mixtures, suggesting that polymer-mediated interfacial effects contribute to solubility enhancement independently of amorphization. Non-sink dissolution testing revealed a non-monotonic, DL-dependent behaviour. At 20% DL, naproxen remained amorphous for at least 2 h, enabling near-congruent drug–polymer release and the highest dissolution performance. At 50% DL, rapid surface crystallization within a dense swollen polymer layer restricted drug release. Unexpectedly, dissolution performance partially recovered at 70% DL despite crystallization, as the reduced polymer fraction generated a more porous hydrated layer that facilitated liquid penetration and drug release compared with 50% DL ASDs and physical mixtures.
Spectroscopic analysis showed progressive loss of hydrogen bonding at intermediate and high DLs, while transient non-specific drug–polymer associations persisted and likely contributed to improved wettability. These findings demonstrate that dissolution enhancement in fast-crystallizing ASDs can be sustained above the amorphous solubility limit when the architecture of the hydrated layer – together with persistent non-specific drug–polymer interactions in aqueous media – governs drug transport rather than amorphous stability alone.
AB - The dissolution behaviour of fast-crystallizing amorphous solid dispersions (ASDs) at drug loadings (DLs) far exceeding the amorphous solubility limit remains poorly understood. In this study, we investigate how extreme DLs influence dissolution mechanisms in naproxen–copovidone VA64 ASDs prepared by hot-melt extrusion at 20, 50, and 70 wt% DL. Rapid post-extrusion cooling was applied at 70% DL to kinetically suppress crystal growth, while lower DL formulations remained amorphous as confirmed by DSC and PXRD. Drug–polymer interactions were analysed using ATR-FTIR combined with principal component analysis.
Saturation solubility measurements revealed moderate advantages of ASDs over physical mixtures, suggesting that polymer-mediated interfacial effects contribute to solubility enhancement independently of amorphization. Non-sink dissolution testing revealed a non-monotonic, DL-dependent behaviour. At 20% DL, naproxen remained amorphous for at least 2 h, enabling near-congruent drug–polymer release and the highest dissolution performance. At 50% DL, rapid surface crystallization within a dense swollen polymer layer restricted drug release. Unexpectedly, dissolution performance partially recovered at 70% DL despite crystallization, as the reduced polymer fraction generated a more porous hydrated layer that facilitated liquid penetration and drug release compared with 50% DL ASDs and physical mixtures.
Spectroscopic analysis showed progressive loss of hydrogen bonding at intermediate and high DLs, while transient non-specific drug–polymer associations persisted and likely contributed to improved wettability. These findings demonstrate that dissolution enhancement in fast-crystallizing ASDs can be sustained above the amorphous solubility limit when the architecture of the hydrated layer – together with persistent non-specific drug–polymer interactions in aqueous media – governs drug transport rather than amorphous stability alone.
KW - dosage form design
KW - oral dosage forms
KW - Amorphous solid dispersions
KW - High drug loading
KW - Copovidone VA64
KW - Fastcrystallizing drugs
KW - Drug–polymer interactions
KW - Hydrated polymer layer
KW - Hot-melt extrusion
KW - Naproxen
KW - bad glass former
UR - https://www.sciencedirect.com/science/article/pii/S0939641126001001?via%3Dihub
UR - https://pubmed.ncbi.nlm.nih.gov/42069265/
UR - https://www.scopus.com/pages/publications/105038983284
U2 - 10.1016/j.ejpb.2026.115079
DO - 10.1016/j.ejpb.2026.115079
M3 - Article
SN - 0939-6411
VL - 224
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
M1 - 115079
ER -